Advertisement

Tumor Biology

, Volume 36, Issue 9, pp 6797–6803 | Cite as

Prognostic significance of SLC9A9 in patients with resectable esophageal squamous cell carcinoma

  • Junying Chen
  • Jing Wen
  • Yuzhen Zheng
  • Hong Yang
  • Kongjia Luo
  • Qianwen Liu
  • Ronggui Hu
  • Zihui Tan
  • Qingyuan Huang
  • Jianhua Fu
Research Article

Abstract

The survival rate of esophageal squamous cell cancer (ESCC) patients is still dismal. Therefore, novel prognostic biomarkers are critically needed for patients with ESCC. SLC9A9 has been reported to be downregulated in hormone-sensitive prostate cancer; however, the correlations between SLC9A9 and ESCC prognosis are unclear. The aim of this study is to evaluate the expression and prognostic significance of SLC9A9 in resectable ESCC. Fresh frozen or paraffin-embedded samples were collected from 167 or 59 patients with resectable ESCC, respectively. The expression of SLC9A9 was assessed by reverse transcription and quantitative real-time polymerase chain reaction analysis (167 patients) and immunohistochemistry (61 patients). The expression of SLC9A9 was not associated with patient clinicopathological characteristics at both transcription and protein levels. The 5-year overall survival in the high SLC9A9 messenger RNA (mRNA) group (n = 106) was poorer than that in the low expression group (n = 61) (34.6 vs. 65.9 %, P < 0.001). Notably, higher SLC9A9 protein expression was also correlated with lower 5-year overall survival (33.1 vs. 66.5 %, P = 0.023). Moreover, multivariate analysis revealed that SLC9A9 mRNA (HR, 2.41; 95 % CI, 1.47–3.97; P = 0.001) and protein (HR, 2.31; 95 %CI, 1.06–5.02; P = 0.034) were independent prognostic factors. In conclusion, the expression of SLC9A9 can be a prognostic predictor for ESCC.

Keywords

SLC9A9 Esophageal squamous cell carcinoma Prognosis 

Notes

Conflicts of interest

None

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. CA Cancer J Clin. 2014;64(1):9–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Enzinger PC, Mayer RJ. N Engl J Med. 2003;349(23):2241–52.CrossRefPubMedGoogle Scholar
  3. 3.
    Orlowski J, Grinstein S. Pflugers Arch. 2004;447(5):549–65.CrossRefPubMedGoogle Scholar
  4. 4.
    Tamura K, Furihata M, Tsunoda T, Ashida S, Takata R, Obara W, et al. Cancer Res. 2007;67(11):5117–25.CrossRefPubMedGoogle Scholar
  5. 5.
    Ng D, Hu N, Hu Y, Wang C, Giffen C, Tang ZZ, et al. Int J Cancer. 2008;123(7):1610–5.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Harguindey S, Orive G, Luis PJ, Paradiso A, Reshkin SJ. Biochim Biophys Acta. 2005;1756(1):1–24.PubMedGoogle Scholar
  7. 7.
    Liu J, Hu Y, Xie X, Fu J. Ann Thorac Surg. 2012;93(2):423–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Saussez S, Cucu DR, Decaestecker C, Chevalier D, Kaltner H, Andre S, et al. Ann Surg Oncol. 2006;13(7):999–1009.CrossRefPubMedGoogle Scholar
  9. 9.
    Rice TW, Rusch VW, Apperson-Hansen C, Allen MS, Chen LQ, Hunter JG, et al. Dis Esophagus. 2009;22(1):1–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Xu XL, Zheng WH, Fu ZX, Li ZP, Xie HX, Li XX, et al. Med Oncol. 2015;32(1):396.CrossRefPubMedGoogle Scholar
  11. 11.
    Ma S, Zhao X. Oncol Rep. 2014;32(4):1631–7.PubMedGoogle Scholar
  12. 12.
    Zhang JY, Bai CY, Bai YQ, Zhang JY, Wu ZY, Wang SH, et al. Hum Pathol. 2014;45(10):2014–22.CrossRefPubMedGoogle Scholar
  13. 13.
    Zhang W, Zhu H, Liu X, Wang Q, Zhang X, He J, et al. Ann Thorac Surg. 2014;98(2):513–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Shibata-Kobayashi S, Yamashita H, Okuma K, Shiraishi K, Igaki H, Ohtomo K, et al. Oncol Lett. 2013;5(3):903–10.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Xu XL, Zheng WH, Tao KY, Li XX, Xu WZ, Wang Y, et al. Med Oncol. 2014;31(11):257.CrossRefPubMedGoogle Scholar
  16. 16.
    Zhao J, Li L, Wei S, Gao Y, Chen Y, Wang G, et al. Dis Esophagus. 2012;25(6):520–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN, et al. Genes Dev. 1997;11(6):701–13.CrossRefPubMedGoogle Scholar
  18. 18.
    Mamidipudi V, Cartwright CA. Oncogene. 2009;28(50):4421–33.CrossRefPubMedGoogle Scholar
  19. 19.
    Dhanasekaran DN, Reddy EP. Oncogene. 2008;27(48):6245–51.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lopez-Bergami P, Habelhah H, Bhoumik A, Zhang W, Wang LH, Ronai Z. Mol Cell. 2005;19(3):309–20.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Lin X, Sikkink RA, Rusnak F, Barber DL. J Biol Chem. 1999;274(51):36125–31.CrossRefPubMedGoogle Scholar
  22. 22.
    Kiely PA, Sant A, O’Connor R. J Biol Chem. 2002;277(25):22581–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Lin X, Sikkink RA, Rusnak F, Barber DL. J Biol Chem. 1999;274(51):36125–31.CrossRefPubMedGoogle Scholar
  24. 24.
    Wang HG, Pathan N, Ethell IM, Krajewski S, Yamaguchi Y, Shibasaki F, et al. Science. 1999;284(5412):339–43.CrossRefPubMedGoogle Scholar
  25. 25.
    Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. Mol Cell Biol. 2001;21(3):893–901.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    West KA, Castillo SS, Dennis PA. Drug Resist Updat. 2002;5(6):234–48.CrossRefPubMedGoogle Scholar
  27. 27.
    Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. Oncogene. 2003;22(56):8983–98.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Junying Chen
    • 1
    • 2
  • Jing Wen
    • 1
    • 2
  • Yuzhen Zheng
    • 1
    • 2
  • Hong Yang
    • 1
    • 2
  • Kongjia Luo
    • 1
    • 2
  • Qianwen Liu
    • 1
    • 2
  • Ronggui Hu
    • 3
  • Zihui Tan
    • 1
    • 2
  • Qingyuan Huang
    • 1
    • 2
  • Jianhua Fu
    • 1
    • 2
  1. 1.State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouChina
  2. 2.Guangdong Esophageal Cancer InstituteGuangzhouChina
  3. 3.General Hospital of Zhongshan CityGuangzhouChina

Personalised recommendations